Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process

Saved in:
Bibliographic Details
Published in:Administrative Law Review
Format: Online Article RSS Article
Published: 2011
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867301668734894080
collection WordPress RSS
FRELIP Feed Integration
container_title Administrative Law Review
description
discipline_display Law
discipline_facet Law
format Online Article
RSS Article
genre Journal Article
id rss_article:65060
institution FRELIP
journal_source_facet Administrative Law Review
publishDate 2011
publishDateSort 2011
record_format rss_article
spellingShingle The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
Law
General
Law
sub_discipline_display General
sub_discipline_facet General
subject_display Law
General
Law
Law
General
Law
subject_facet Law
General
Law
title The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
title_auth The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
title_full The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
title_fullStr The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
title_full_unstemmed The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
title_short The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA's Biosimilar Approval Process
title_sort the illusion of interchangeability: the benefits and dangers of guidance-plus rulemaking in the fda's biosimilar approval process
topic Law
General
Law
url https://digitalcommons.wcl.american.edu/alr/vol63/iss3/6